Skip to content
10-Q

Quarterly Report

JASPER THERAPEUTICS, INC. JSPR JSPRW

0001213900-26-056595

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 28M sh
Shares Diluted Q1 2026 · Mar 31, 2026 28.67M sh
Shares Diluted Q1 2026 · Mar 31, 2025 15.02M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$14.55M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$22.84M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $14.14M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $28.69M
Stockholders Equity Q1 2026 · Mar 31, 2026 $3.4M
Stockholders Equity Q1 2026 · Dec 31, 2025 $4.15M
Stockholders Equity Q1 2026 · Mar 31, 2025 $42.24M
Stockholders Equity Q1 2026 · Dec 31, 2024 $61.67M
Current Liabilities Q1 2026 · Mar 31, 2026 $9M
Current Liabilities Q1 2026 · Dec 31, 2025 $13.2M
Total Liabilities Q1 2026 · Mar 31, 2026 $17.78M
Total Liabilities Q1 2026 · Dec 31, 2025 $31.63M
Current Assets Q1 2026 · Mar 31, 2026 $20.29M
Current Assets Q1 2026 · Dec 31, 2025 $34.65M
Total Assets Q1 2026 · Mar 31, 2026 $21.18M
Total Assets Q1 2026 · Dec 31, 2025 $35.78M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.04
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.41
Eps Basic Q1 2026 · Mar 31, 2026 −$0.04
Eps Basic Q1 2026 · Mar 31, 2025 −$1.41
Sga Expense Q1 2026 · Mar 31, 2026 $5.14M
Sga Expense Q1 2026 · Mar 31, 2025 $5.65M
Rd Expense Q1 2026 · Mar 31, 2026 $5.81M
Rd Expense Q1 2026 · Mar 31, 2025 $16.16M
Net Income Q1 2026 · Mar 31, 2026 −$1.17M
Net Income Q1 2026 · Mar 31, 2025 −$21.24M
Operating Income Q1 2026 · Mar 31, 2026 −$10.95M
Operating Income Q1 2026 · Mar 31, 2025 −$21.8M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $3.62M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $9.76M